Intrexon Forms Multi-Year Collaboration with New Dedicated Fund
Intending to Launch Up to Ten Intrexon-Enabled Startups per Year GERMANTOWN, Md., June 15, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON) announced today that it has entered into a collaboration with an investment fund sponsored by Harvest Capital Strategies, LLC. The fund is believed to be the world's first that is dedicated to the inventions and discoveries of a single company. Intrexon has agreed to provide the fund a significant number of investment proposals from across five sectors – Health, Energy, Food, Environment and Consumer – that are suitable for pursuit by a startup, including several in 2015.  With respect to such proposals, Intrexon will provide the fund with...
Intrexon and Oragenics Expand Collaboration to Pursue Development of Biotherapeutics for the Oral Cavity
Companies to Progress ActoBiotic™ AG013 for Treatment of Oral Mucositis Oragenics Now A Clinical Stage Company June 10, 2015 08:15 AM Eastern Daylight Time GERMANTOWN, Md. & TAMPA, Fla.--(BUSINESS WIRE)--Intrexon Corporation (NYSE:XON), a leader in synthetic biology, and Oragenics (NYSE MKT:OGEN), today announced a new Exclusive Channel Collaboration (ECC) to pursue development of biotherapeutics for oral mucositis (OM) and other diseases and conditions of the oral cavity, throat, and esophagus, including clinical advancement of the ActoBiotic™ AG013 for the treatment of OM. OM results in the painful inflammation and ulceration of...
Fibrocell and Intrexon Announce Positive in vitro Pre-Clinical Data for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) at European Society of Human Genetics
Findings Advance Gene-Therapy Drug Candidate as Potential First-in-Class Treatment for RDEB-a Rare, Congenital, Devastating Skin Disease EXTON, Pa. and GERMANTOWN, Md., June 8, 2015 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (Nasdaq:FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet needs, and Intrexon Corporation (NYSE:XON), a leader in synthetic biology, today announced positive in vitro pre-clinical data for Fibrocell's lead orphan gene-therapy drug candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The data were presented in ...
Intrexon Announces Distribution Ratio for Distribution of ZIOPHARM Shares
GERMANTOWN, Md., June 5, 2015 /PRNewswire/ -- Intrexon Corporation ("Intrexon") (NYSE: XON), a leader in synthetic biology, today announced that it has determined the final distribution ratio relating to its previously announced distribution of all of its 17,830,305 shares of ZIOPHARM Oncology, Inc. ("ZIOPHARM") (NASDAQ: ZIOP) common stock on or about June 12, 2015, the distribution date, as a pro rata dividend on shares of Intrexon common stock, and on warrants to purchase shares of Intrexon common stock ("Warrants"), outstanding on June 4, 2015, the record date. Based on the number of Intrexon shares outstanding and shares deliverable under Warrants as of the record date, holders of I...
1